Data on analysis of MK-801 bioavailability in mouse plasma and brain tissue by ultra-performance liquid chromatography-tandem mass spectrometry

Baiba Svalbe,Solveiga Grinberga,Gundega Stelfa,Edijs Vavers,Baiba Zvejniece,Eduards Sevostjanovs,Maija Dambrova,Liga Zvejniece

doi:10.1016/j.dib.2019.104623

Abstract

MK-801, a N-methyl-d-aspartate receptor antagonist, is widely used in animal preclinical experiments to induce memory and learning impairments and schizophrenia-like behavior. In the present study, we compared the plasma and brain tissue concentrations of MK-801 after intraperitoneal (i.p.) or subcutaneous (s.c.) administration at a dose of 0.1 mg/kg in male ICR mice. Moreover, these data present the optimization of ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for the analysis of MK-801 in biological samples. Procedures for the preparation of brain tissue and plasma samples and instrumental analysis are described. This article is related to a research article entitled “Effects of the N-methyl-d-aspartate receptor antagonist, MK-801, on spatial memory and influence of the route of administration” [1].

Highlights

MK-801, a N-methyl-D-aspartate receptor antagonist, is widely used in animal preclinical experiments to induce memory and learning impairments and schizophrenia-like behavior
MK-801 concentration was determined by ultra-performance liquid chromatography-tandem mass spectrometry
The data present concentrations of MK-801 in mouse brain tissue and plasma after s.c. and i.p. administration, which is important for experiment planning in experimental neuroscience

Summary

Data accessibility

The data present concentrations of MK-801 in mouse brain tissue and plasma after s.c. and i.p. administration, which is important for experiment planning in experimental neuroscience. 4. The data presented in this data article show that the concentration of MK-801 in brain tissues and plasma depend on the route of administration. The concentration of MK-801 was measured in blood plasma and brain tissue 15, 30, 60, 120, and 240 min after a single i.p. or s.c. administration of MK-801 at a dose of 0.1 mg/kg. The concentration of MK-801 in blood plasma was significantly higher following s.c. injection than following i.p. administration until the 60-min (Fig. 4B). The maximal concentration (Cmax) of MK-801 in brain tissue and blood plasma were almost 2-fold higher when administered via the s.c. route than the i.p. route (Table 2).

Animals

MK-801 administration

Findings

Statistical analysis